Macular degeneration treatment linked to blindness, FDA advisory says

Share this article:

Injections of the cancer drug Avastin, which is also a treatment for the wet form of age-related macular degeneration, has been linked to reports of blindness.

Twelve patients in at least three separate clinics developed the serious bacterial infection Streptococcus endophthalmitis after undergoing injections of Avastin, which is administered in tiny doses to the eye, according to a Food and Drug Administration advisory issued Aug. 30. At least five of these patients have lost all remaining vision in the eyes that were treated with Avastin.

The infections have been traced back to a compounding pharmacy in Hollywood, FL, which repackaged intravitreal injections of Avastin from injectable 100-mg/4- mL, single-use vials into individual 1-mL single-use syringes. Officials say the repackaging process can open the door for bacterial contamination.

This is another blow to Avastin as an eye treatment. Recent studies have found Avastin to be as effective as its competitor Lucentis in treating macular degeneration in seniors, for a fraction of the price. Lucentis costs $2,000 per injection while Avastin costs just $50 per dose. Genentech manufactures both drugs.

Share this article:

More in News

Long-term care continues to lead in deal volume and value: PwC report

Long-term care continues to lead in deal volume ...

Long-term care bucked healthcare industry trends with strong merger and acquisition activity in the second quarter of 2014, according to newly released data from professional services firm PricewaterhouseCoopers.

Empowering nurse practitioners could reduce hospitalizations from SNFs, study finds

Granting more authority to nurse practitioners is associated with reduced hospitalization of skilled nursing facility residents, according to recently published findings.

Pioneer ACO drops out of program, despite reductions in skilled nursing utilization

A California healthcare system has become the latest dropout from the Pioneer Accountable Care Organization program, despite reducing skilled nursing facility utilization and improving its readmission rates. Sharp HealthCare announced its decision in a quarterly financial statement released Tuesday.